GlaxoSmithKline Pharma a market performer: P Lilladher

Published on Tue, Jun 03, 2008 at 14:11 |  Source : Moneycontrol.com

Updated at Tue, Jun 03, 2008 at 14:16  

9361 Investors following GlaxoSmithKline. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

Prabhudas Lilladher has maintained its market performer rating on GlaxoSmithKline Pharmaceuticals with a price target of Rs 1,136 in its May 30, 2008 research report. "Glaxo Smithkline Pharma (GSK) has undertaken new initiatives for future growth of the company. The new initiatives are: 1) Developing channels for hospitals to leverage GSK scale, optimise marketing spends and develop expertise. 2) Develop channels and reach for tapping rural opportunity, expanding matured products through contract field force. 3) Investing in chronic therapeutic segments like diabetes, CVS, biological. Strengthen dermatology and critical care franchises."

"At the CMP of Rs 1,139, the stock trades at 21.5x CY08E EPS of Rs 53 and 19.1x CY09E EPS of Rs 59.8. We maintain Market Performer rating on the scrip with a price target of Rs 1,136 (19x CY09 earnings)," says Lilladher's research report.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

For further details click on attachment......

  

More on Moneycontrol

Trending News

Business News

Iran's blocking internet access
Rupee rally may stall with fall against US dollar, euro "Rupee rally may stall with fall against US dollar, euro"

Sources Say Attorney General To Decide On Filing A Review Plea

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 11 2012, 11:52 | Source: CNBC-TV18

TCS to expand centers in N.America; CY12 focus on Japan  

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com